Back to Browse Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice

Authors Lee S, Kim MS, Lee D, Kwon TK, Khang D, Yun HS, Kim SH

Published Date January 2013 Volume 2013:8(1) Pages 147—158

DOI http://dx.doi.org/10.2147/IJN.S39534

Received 24 October 2012, Accepted 24 November 2012, Published 7 January 2013

Soyoung Lee,1,* Mi-Sun Kim,1,* Dakeun Lee,2 Taeg Kyu Kwon,3 Dongwoo Khang,4 Hui-Suk Yun,5 Sang-Hyun Kim1

1CMRI, Laboratory of Immunotoxicology, Department of Pharmacology,School of Medicine, Kyungpook National University, Daegu, Republic of Korea; 2Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; 3Department of Immunology, School of Medicine, Keimyung University, Daegu, Republic of Korea; 4School of Nano and Advanced Materials Science and Engineering, Gyeongsang National University, Jinju, Republic of Korea; 5Engineering Ceramics Department, Powder and Ceramics Division, Korea Institute of Materials Science, Changwon, Republic of Korea

*These authors contributed equally to this work

Background: Mesoporous silica (MPS) nanoparticles (NPs), which have a unique pore structure and extremely large surface area and pore volume, have received much attention because of their biomedical application potential. Using MPS NPs for biomedical devices requires the verification of their biocompatibility because the surface area of NPs is one of the most important determinants of toxicity, including the cellular uptake and immune response. We have previously reported that the cytotoxicity and inflammation potential of MPS NPs have been shown to be lower than those of general amorphous colloidal silica (Col) NPs in macrophages, but the low cytotoxicity does not guarantee high biocompatibility in vivo. In this study, we compared the in vivo immunotoxicity of MPS and Col NPs in the mouse model to define the effects of pore structural conditions of silica NPs.
Materials and methods: Both MPS and Col NPs (2, 20, and 50 mg/kg/day) were intraperitoneally administered in female BALB/c mice for 4 weeks, and clinical toxicity, lymphocyte population, serum IgG/IgM levels, and histological changes were examined.
Results: There was no overt sign of clinical toxicity in either MPS- or Col-treated mice. However, MPS NPs led to significant increases in liver and spleen weight and splenocyte proliferation. Mice treated with MPS NPs showed altered lymphocyte populations (CD3+, CD45+, CD4+, and CD8+) in the spleen, increased serum IgG and IgM levels, and histological changes. Despite slight changes in lymphocyte populations in the spleen, Col NPs did not alter other immunological factors.
Conclusion: The results indicate that in vivo exposure to MPS NPs caused more damage to systemic immunity than that of Col NPs through the dysregulation of the spleen. The results for in vivo data are inconsistent with those for in vitro data, which show lower cytotoxicity for MPS NPs. These results suggest the importance of verifying biocompatibility both in vitro and in vivo during the design of new nanomaterials.

Keywords: immunotoxicity, mesoporous silica nanoparticle, colloidal silica nanoparticle, spleen

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability

Neves AR, Lúcio M, Martins S, Lima JL, Reis S

International Journal of Nanomedicine 2013, 8:177-187

Published Date: 7 January 2013

Effects of a hybrid micro/nanorod topography-modified titanium implant on adhesion and osteogenic differentiation in rat bone marrow mesenchymal stem cells

Zhang WJ, Li ZH, Huang QF, Xu L, Li JH, Jin YQ, Wang GF, Liu XY, Jiang XQ

International Journal of Nanomedicine 2013, 8:257-265

Published Date: 11 January 2013

Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics

Tan Q, Jiang R, Xu M, Liu G, Li S, Zhang J

International Journal of Nanomedicine 2013, 8:737-745

Published Date: 20 February 2013

Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy

Enriquez GG, Rizvi SAA, D’Souza MJ, Do DP

International Journal of Nanomedicine 2013, 8:1393-1402

Published Date: 10 April 2013

Enhancing the bioactivity of Poly(lactic-co-glycolic acid) scaffold with a nano-hydroxyapatite coating for the treatment of segmental bone defect in a rabbit model

Wang DX, He Y, Bi L, Qu ZH, Zou JW, Pan Z, Fan JJ, Chen L, Dong X, Liu XN, Pei GX, Ding JD

International Journal of Nanomedicine 2013, 8:1855-1865

Published Date: 9 May 2013